
News|Articles|March 1, 2011
FDA Pipeline Preview, March 2011 (Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib)
Recent FDA action (through, February 2011) related to Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib.
Advertisement
Complete response
Fast-track designation
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ACIP to vote on major hepatitis B vaccine update that could reshape the childhood vaccine schedule
2
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
3
ACIP votes to end universal birth-dose for hepatitis B vaccine with updated guidance for parents and doctors
4
New test may solve the specificity and false-positive problems of the PSA test for prostate cancer
5





















































